Literature DB >> 25457822

QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway.

X Fu1, Y Feng2.   

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most frequently occurring malignancies in the world. The RNA-binding protein quaking (QKI) is a newly identified tumour suppressor in multiple cancers, but its role in OSCC is currently unknown. The purpose of the present study was to clarify the relationship between QKI expression and OSCC development. We found QKI-5 expression to be significantly decreased in the oral cancer cell line CAL-27. QKI-5 overexpression also reduced the proliferation of CAL-27 cells, which correlated with cyclin D1. This regulative function of QKI-5 occurs by modulating the phosphorylation level of the mitogen-activated protein kinase (MAPK) pathway. Therefore this study shows that underexpression of tumour suppressor QKI-5 could activate the MAPK pathway and contribute to uncontrolled cyclin D1 expression, thus resulting in increased proliferation of oral cancer cells.
Copyright © 2014 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MAPK signalling pathway; QKI-5; RNA-binding protein; cyclin D1; oral squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25457822     DOI: 10.1016/j.ijom.2014.10.001

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  15 in total

1.  Mitogen-activated protein kinase signaling pathway in oral cancer.

Authors:  Qian Peng; Zhiyuan Deng; Hao Pan; Liqun Gu; Ousheng Liu; Zhangui Tang
Journal:  Oncol Lett       Date:  2017-11-24       Impact factor: 2.967

2.  Hydrogen Sulfide Is Increased in Oral Squamous Cell Carcinoma Compared to Adjacent Benign Oral Mucosae.

Authors:  Andrew T Meram; Jie Chen; Stavan Patel; Dongsoo D Kim; Brett Shirley; Paul Covello; Domenico Coppola; Eric X Wei; Ghali Ghali; Christopher G Kevil; Rodney E Shackelford
Journal:  Anticancer Res       Date:  2018-07       Impact factor: 2.480

3.  RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.

Authors:  Rui-Li Zhang; Jun-Ping Yang; Li-Xia Peng; Li-Sheng Zheng; Ping Xie; Meng-Yao Wang; Yun Cao; Zhi-Ling Zhang; Fang-Jian Zhou; Chao-Nan Qian; Yong-Xing Bao
Journal:  Cell Cycle       Date:  2016-10-21       Impact factor: 4.534

4.  Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy.

Authors:  Keke Zhang; Fei Yan; Xiaoying Lei; Di Wei; Huanyu Lu; Zheng Zhu; An Xiang; Zichen Ye; Li Wang; Wanxiang Zheng; Xi'an Li; Jiarui Yuan; Zifan Lu; Jianlin Yuan
Journal:  Mol Med Rep       Date:  2018-04-13       Impact factor: 2.952

Review 5.  Immune and genomic signatures in oral (head and neck) cancer.

Authors:  Prasenjit Chakraborty; Tanusri Karmakar; Neeraj Arora; Geetashree Mukherjee
Journal:  Heliyon       Date:  2018-11-02

6.  A novel long non-coding RNA, AC012456.4, as a valuable and independent prognostic biomarker of survival in oral squamous cell carcinoma.

Authors:  Xuegang Hu; Zailing Qiu; Jianchai Zeng; Tingting Xiao; Zhihong Ke; Hongbing Lyu
Journal:  PeerJ       Date:  2018-08-13       Impact factor: 2.984

7.  LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.

Authors:  Meng Wu; Yawei Huang; Tongchang Chen; Weichao Wang; Shiguang Yang; Zhenfeng Ye; Xiaoqing Xi
Journal:  J Cell Mol Med       Date:  2018-11-22       Impact factor: 5.310

8.  QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling.

Authors:  Fei Shi; Zheng Deng; Zheng Zhou; Chen-Yi Jiang; Rui-Zhe Zhao; Feng Sun; Di Cui; Xiao-Yu Bei; Bo-Yu Yang; Qian Sun; Xing-Jie Wang; Qi Wu; Shu-Jie Xia; Bang-Min Han
Journal:  J Cell Mol Med       Date:  2019-08-26       Impact factor: 5.310

9.  MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma.

Authors:  Zhenyue He; Jun Yi; Xiaolong Liu; Jing Chen; Siqi Han; Li Jin; Longbang Chen; Haizhu Song
Journal:  Mol Cancer       Date:  2016-06-29       Impact factor: 41.444

10.  The miR-17-92 cluster/QKI2/β-catenin axis promotes osteosarcoma progression.

Authors:  Hongbo Yang; Zhibin Peng; Min Liang; Yubo Zhang; Yangyang Wang; Tianwen Huang; Yudong Jiang; Bo Jiang; Yansong Wang
Journal:  Oncotarget       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.